Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could flickering light help Parkinson's patients walk freely?

NCT ID NCT06295458

Symptom relief Sponsor: Emory University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 2 times

Summary

This study tests whether daily exposure to a flickering gamma light is safe and tolerable for people with Parkinson's disease who experience freezing of gait—a sudden inability to step forward. Researchers will monitor side effects and see if the light therapy reduces freezing episodes. The study involves 24 participants using a light device at home for one hour each day.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

24 people

The number who actually took part.

Started

Jul 2024

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PD Diagnosis by UK Brain Bank Criteria * Hoehn \& Yahr stage I-IV in the off-state * FOG noted in medical history * FOG confirmed visually by the examiner in the office * PD that is levodopa-treated and responsive * Able to manage 12 hours of "OFF" dopaminergic medication state * Age 50-80 years * Able to sign a consent document and willing to participate in all aspects of the study Exclusion Criteria: * A diagnosis of atypical Parkinsonism, including vascular Parkinsonism * Prior treatment with medications that cause Parkinsonism * Stage V PD -unable to walk independently when OFF * Absence of levodopa response * Neurological or orthopedic disorders interfering with gait * Dementia precluding completing the study protocol, including those meeting criteria for dementia with Lewy bodies * Major depression based on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria * Any medical problems that would preclude participation, including individuals with a history of migraines, tinnitus, or seizures, because sensory stimuli can potentially exacerbate these conditions. * Profound sensory loss as determined by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gait disorders, neurologic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Gait Disorders, Neurologic Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gait disorders, neurologic Parkinson disease

Contacts and locations

Locations

  • Emory Movement Disorders Center

    Atlanta, Georgia, 30329, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.